Brought to you by 
SDP enters MOU worth potential $3bn for option to buy up to 11 Roivant vants; later signs definitive agreement, then completes M&A
01 Jun 2022
Executive Summary
Through a non-binding memorandum of understanding (MOU), Sumitomo Dainippon Pharma Co. Ltd. (SDP) and Roivant Sciences Inc. plan to forge an alliance involving the clinical-stage assets of multiple Roivant biopharmaceutical divisions (known as vants). The potential partners will conduct due diligence and expect to sign a definitive agreement by the end of October 2019.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SDP enters MOU worth potential $3bn for option to buy up to 11 Roivant vants; later signs definitive agreement, then completes M&A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice